Aranesp is a medicine used to treat anaemia (low red blood cell counts) that is causing symptoms. It is used in two groups of patients:
- adults and children with chronic renal failure (long-term, decreasing in the ability of the kidneys to work properly);
- adults who are receiving chemotherapy for non‑myeloid cancer (cancer not originating in the bone marrow).
Aranesp contains the active substance darbepoetin alfa.
Aranesp : EPAR - Medicine overview (PDF/80.72 KB)
First published: 07/11/2007
Last updated: 14/05/2019
Aranesp : EPAR - Risk-management-plan summary (PDF/50.68 KB)
First published: 14/05/2019
Last updated: 13/01/2020
|Agency product number||
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
|Anatomical therapeutic chemical (ATC) code||
Amgen Europe B.V.
|Date of issue of marketing authorisation valid throughout the European Union||
19/02/2021 Aranesp - EMEA/H/C/000332 - IB/0153
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adults and paediatric patients.
Treatment of symptomatic anaemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy.